HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.390
-0.001 (-0.26%)
At close: Feb 21, 2025, 4:00 PM
0.374
-0.016 (-4.10%)
After-hours: Feb 21, 2025, 7:48 PM EST
HCW Biologics Revenue
HCW Biologics had revenue of $426.42K in the quarter ending September 30, 2024, a decrease of -50.02%. This brings the company's revenue in the last twelve months to $3.50M, up 22.27% year-over-year. In the year 2023, HCW Biologics had annual revenue of $2.84M, down -57.72%.
Revenue (ttm)
$3.50M
Revenue Growth
+22.27%
P/S Ratio
4.15
Revenue / Employee
$77,689
Employees
45
Market Cap
17.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
Dec 31, 2022 | 6.72M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 4.10M | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HCWB News
- 19 days ago - HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial - GlobeNewsWire
- 5 weeks ago - HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 - GlobeNewsWire
- 2 months ago - HCW Biologics Inc. Received NASDAQ Staff Determination Letter - GlobeNewsWire
- 3 months ago - HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - GlobeNewsWire
- 3 months ago - Why Is Penny Stock HCW Biologics Surging On Monday? - Benzinga
- 3 months ago - HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate - GlobeNewsWire
- 3 months ago - HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction - GlobeNewsWire